Results 91 to 100 of about 5,054 (206)
JCC Plus, Volume 1, Issue 5, September 2026.ABSTRACT Background and Aims In this exploratory post hoc analysis of the phase 3 VIVID‐1 (NCT03926130) study, we evaluate early and sustained treatment effects of mirikizumab on individual disruptive CD symptoms—stool frequency (SF), abdominal pain (AP), bowel urgency (BU) and fatigue—in non‐biologic‐failed (NBF) and biologic‐failed (BF) patients and ...
Axel Dignass +12 more
wiley +1 more source
JGH Open, Volume 10, Issue 9, September 2026.ABSTRACT Background Despite limited extent, patients with ulcerative proctitis (UP) can suffer from debilitating symptoms, complications, and risk of disease extension. The aim was to provide a contemporary real‐world insight into the management and outcomes of UP.
Sreecanth S. Raja +9 more
wiley +1 more source
JEADV Clinical Practice, Volume 5, Issue 3, Page 933-938, September 2026.ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange +4 more
wiley +1 more source
Le guselkumab, inhibiteur de l’interleukine 23, efficace dans le traitement du psoriasis
, 2018 Le guselkumab est un inhibiteur sélectif de l’interleukine (IL) 23, commercialisé et remboursé en Belgique depuis peu. Nous avons réalisé une revue de littérature afin d’éclaircir son efficacité et sa sécurité.[Guselkumab, an effective interleukin-23 ...
Colmant, Caroline +1 more
core
JEADV Clinical Practice, Volume 5, Issue 3, Page 986-988, September 2026.ABSTRACT Nail psoriasis is a prevalent chronic inflammatory disorder that affects the nail unit and is often accompanied by psoriatic skin lesions. It is also more likely to progress to psoriatic arthritis. Here, we report the case of a 57‐year‐old woman who presented with a 3‐year history of nail dystrophy, scaling erythema, and psoriatic plaques on ...
Tianmeng Yan, Xiaoyan Wu, Zhenying Zhang
wiley +1 more source
Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances
MedComm, Volume 7, Issue 9, September 2026.Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait +5 more
wiley +1 more source
Indian Journal of DermatologyBackground: Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response.
Xiuqiu Lin +5 more
doaj +1 more source
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 729-747, September 2026.The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins +6 more
wiley +1 more source
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
Fabrizio Martora, Teresa Battista,* Luca Potestio,* Antonio Portarapillo, Nello Tommasino, Matteo Megna Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy*These authors ...
Tommasino N +5 more
core